Chiffres en millions de dollars américains. L'exercice financier va de février à janvier.
Breakdown
TTM
04/30/2025
04/30/2024
04/30/2023
04/30/2022
04/30/2021
Revenus
58
56
50
53
49
41
Croissance des revenus (H/H)
9%
12%
-6%
8%
20%
28%
Coût des ventes
29
28
29
29
23
21
Bénéfice brut
29
28
20
24
25
19
Vente, Général et Administration
18
16
18
17
15
12
Recherche et développement
8
6
9
11
9
7
Frais d'exploitation
26
23
27
28
24
19
Autres revenus (charges) non opérationnels
0
0
--
0
0
0
Bénéfice avant impôts
2
4
-7
-5
0
0
Charge d'impôt sur le revenu
0
0
0
0
0
0
Bénéfice net
2
4
-7
-5
0
0
Croissance du bénéfice net
--
-157%
40%
--
--
-100%
Actions en circulation (diluées)
14.45
14.26
13.54
13.54
14.16
14.57
Variation des actions (H-H)
3%
5%
0%
-4%
-3%
23%
EPS (dilué)
0.16
0.32
-0.53
-0.39
0.04
0.02
Croissance du EPS
-442%
-161%
38%
-1,075%
100%
-112%
Flux de trésorerie libre
5
6
-6
1
4
-4
Flux de trésorerie libre par action
--
--
--
--
--
--
Marge brute
50%
50%
40%
45.28%
51.02%
46.34%
Marge opérationnelle
3.44%
7.14%
-12%
-7.54%
0%
0%
Marge bénéficiaire
3.44%
7.14%
-14%
-9.43%
0%
0%
Marge du flux de trésorerie libre
8.62%
10.71%
-12%
1.88%
8.16%
-9.75%
EBITDA
3
5
-5
-2
1
1
Marge EBITDA
5.17%
8.92%
-10%
-3.77%
2.04%
2.43%
D&A pour le résultat opérationnel
1
1
1
2
1
1
EBIT
2
4
-6
-4
0
0
Marge EBIT
3.44%
7.14%
-12%
-7.54%
0%
0%
Taux d'imposition effectif
0%
0%
0%
0%
0%
0%
Statistiques clés
Clôture préc.
$6.55
Prix d'ouverture
$6.54
Plage de la journée
$6.12 - $6.56
Plage de 52 semaines
$5.59 - $11.82
Volume
13.2K
Volume moyen
12.2K
BPA (TTM)
0.17
Rendement en dividend
--
Capitalisation boursière
$84.3M
Qu’est-ce que CSBR ?
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company is headquartered in Hackensack, New Jersey and currently employs 213 full-time employees. The firm is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions (TOS). This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. The company also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.